文献速递肿瘤 PET/CT核素与放射性配体治疗

C-X-C趋化因子受体4靶向分子影像对晚期肾上腺皮质癌患者的预后预测价值

Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-06-19

本研究纳入41例转移性肾上腺皮质癌(ACC)患者,评估[68Ga]Ga-PentixaFor PET/CT中CXCR4靶向分子影像的预后预测价值。结果显示,较高的肿瘤细胞表面趋化因子受体结合量(TRB)是总生存期(OS)的独立预测因子,而其他影像和临床参数未能提供相关预后信息。

要点

  • 在晚期ACC中,[68Ga]Ga-PentixaFor PET/CT测量的较高TRB是OS的独立预测因子。
  • CXCR4阳性腹膜转移与较短OS相关(HR 2.03)。
  • 其他影像和临床参数未能提供相关预后信息。

核心结论

  • 在晚期ACC中,通过[68Ga]Ga-PentixaFor PET/CT检测到的肿瘤细胞表面趋化因子受体结合量升高是OS的独立预测因子,而其他影像和临床参数未能提供相关预后信息。

研究设计与样本

  • 本研究识别了41例接受[68Ga]Ga-PentixaFor PET/CT显像的转移性ACC患者,通过手动分割肿瘤负荷进行视觉和定量评估,并提供肿瘤体积、峰值/平均/最大标准化摄取值和肿瘤趋化因子受体结合量(TRB,定义为SUVmean乘以肿瘤体积)。
  • 临床参数包括性别、既往治疗、年龄、Weiss评分和Ki67指数。
  • 影像检查后记录总生存期(OS)。

主要发现

  • [68Ga]Ga-PentixaFor PET/CT后中位OS为9个月(范围1-96个月)。
  • 单变量分析中,仅较高的TRB(每10 ml,HR 1.004,95%CI:1.0001-1.007,P=0.005)和存在CXCR4阳性腹膜转移(PM)与较短OS相关(HR 2.03,95%CI:1.03-4.02,P=0.04)。
  • 存在CXCR4阳性肝转移(LM)趋势 towards 显著性(HR 1.85,95%CI:0.9-4.1,P=0.11),而所有其他参数未能预测生存。
  • 多变量分析中,仅TRB是OS的独立预测因子(HR 1.0,95%CI:1.00-1.001,P=0.02)。
  • Kaplan-Meier分析中,TRB高于中位数(13.3个月 vs. 低于中位数,6.4个月)和存在CXCR4阳性PM(6.4个月 vs. 无PM,11.4个月)与较短生存相关(P分别<0.05);存在LM也与较差结局相关(8.5个月 vs. 无LM,18.1个月),但未达到显著性(P=0.07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients affected with adrenocortical carcinoma (ACC), C-X-C motif chemokine receptor 4 (CXCR4) is highly expressed in sites of disease in an ex-vivo setting. We aimed to determine the predictive value of CXCR4-targeting [68Ga]Ga-PentixaFor PET/CT for outcome when compared to clinical parameters. METHODS: We identified 41 metastasized ACC patients imaged with [68Ga]Ga-PentixaFor PET/CT. Scans were assessed visually and on a quantitative level by manually segmenting the tumor burden (providing tumor volume [TV], peak/mean/maximum standardized uptake values [SUV] and tumor chemokine receptor binding on the cell surface [TRB], defined as SUVmean multiplied by tumor volume). Clinical parameters included sex, previous therapies, age, Weiss-Score, and Ki67 index. Following imaging, overall survival (OS) was recorded. RESULTS: After [68Ga]Ga-PentixaFor PET/CT, median OS was 9 months (range, 1-96 months). On univariable analysis, only higher TRB (per 10 ml, HR 1.004, 95%CI: 1.0001-1.007, P = 0.005) and presence of CXCR4-positive peritoneal metastases (PM) were associated with shorter OS (HR 2.03, 95%CI: 1.03-4.02, P = 0.04). Presence of CXCR4-positive liver metastases (LM) trended towards significance (HR 1.85, 0.9-4.1, P = 0.11), while all other parameters failed to predict survival. On multivariable analysis, only TRB was an independent predictor for OS (HR 1.0, 95%CI: 1.00-1.001, P = 0.02). On Kaplan-Meier analysis, TRB above median (13.3 months vs. below median, 6.4 months) and presence of CXCR4-positive PM (6.4 months, vs. no PM, 11.4 months) were associated with shorter survival (P < 0.05, respectively). Presence of LM, however, was also linked to less favorable outcome (8.5 months vs. no LM, 18.1 months), without reaching significance (P = 0.07). CONCLUSIONS: In advanced ACC, elevated tumor chemokine receptor binding on the tumor cell surface detected through [68Ga]Ga-PentixaFor PET/CT is an independent predictor for OS, while other imaging and clinical parameters failed to provide relevant prognostic information.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Schloetelburg W, Hartrampf PE, Kosmala A, et al. Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma. Eur J Nucl Med Mol Imaging. 2024. PMID: 38896128. doi:10.1007/s00259-024-06800-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。